Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8 Purity > 98.0% (GC) Lenvatinib Mesylate Intermediate Factory

Lus piav qhia luv luv:

Lub npe tshuaj: Methyl 4-Amino-2-Methoxybenzoate

CAS: 27492-84-8 Nr

Purity:> 98.0% (GC)

Cov tsos mob: Dawb rau Off-White Powder lossis Crystals

Intermediate ntawm Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com


Product Detail

Yam khoom

Khoom cim npe

Nqe lus piav qhia:

Chemical Properties:

Tshuaj npe Methyl 4-Amino-2-Methoxybenzoate
Synonyms 4-Amino-2-Methoxybenzoic Acid Methyl Ester;Methyl 4-Amino-o-Anisate;4-Amino-o-Anisic Acid Methyl Ester
CAS Nr 27492-84-8
CAT Number RF-PI 1974, UA
Tshuag xwm txheej Nyob rau hauv Tshuag, ntau lawm Scale mus txog Tons
Molecular Formula C9H11NO3
Molecular Luj 181.19 Nws
Qhov ntom 1.179 ± 0.060g / cm3
Hom Ruifu Tshuaj

Specifications:

Yam khoom Specifications
Qhov tshwm sim Dawb rau Off-White Powder lossis Crystals
Purity / Analysis Method > 98.0% (GC)
Purity / Analysis Method 97.5 ~ 102.5 (Nonaqueous Titration)
Melting Point 157.0 ~ 161.0 ℃
Poob rau ziab <1.00%
Tag nrho cov impurities <2.0%
Infrared Spectrum Raws li tus qauv
Proton NMR Spectrum Raws li tus qauv
Test Standard Enterprise Standard
Kev siv Intermediate ntawm Lenvatinib Mesylate (CAS: 857890-39-2)

Pob & Cia:

Pob: Lub raj mis, Aluminium ntawv ci hnab, 25kg / Cardboard Nruas, los yog raws li tus neeg yuav tsum tau muaj

Cia txias:Khaws rau hauv cov thawv ntim khoom ntawm qhov chaw txias thiab qhuav;Tiv thaiv los ntawm lub teeb thiab noo noo

Qhov zoo:

1

FAQ:

Daim ntawv thov:

Methyl 4-Amino-2-Methoxybenzoate (CAS: 27492-84-8) tuaj yeem siv los ua ib qho nruab nrab ntawm Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib yog cov tshuaj kho mob qog noj ntshav uas tsim los ntawm Eisai Corporation ntawm Nyiv (Code: E7080), koom nrog cov inhibitor ntawm qhov ncauj ntau tus tyrosine kinase (RTK) thiab tuaj yeem cuam tshuam kinase kev ua ntawm vascular endothelial kev loj hlob yam (VEGF) Receptors VEGFR1 ( FLT1), VEGFR2 (KDR), thiab VEGFR3 (FLT4).Lenvatinib tseem tuaj yeem cuam tshuam kev koom tes ntawm lwm cov RTKs hauv pathological angiogenesis, qog loj hlob, thiab kev mob qog noj ntshav tshwj tsis yog rau lawv cov kev ua haujlwm ntawm tes xws li fibroblast kev loj hlob (FGF) receptors FGFR1, 2, 3, thiab 4;platelet-derived growth factor receptor (PDGFR [alpha]), KIT, thiab RET.[Cov Lus Qhia]: Lenvatinib yog qhov tsim nyog rau kev kho mob ntawm cov neeg mob qog nqaij hlav qog noj ntshav hauv zos lossis hom metastasis, hom kev nce qib thiab hom xov tooj cua iodine-refractory txawv.Thaum Lub Ob Hlis 13, 2015, US FDA tau pom zoo tshuaj tiv thaiv kab mob Lenvatinib rau kev kho mob qog noj ntshav.Lenvatinib yog ntau lub hom phiaj enzyme inhibitor, muaj peev xwm inhibiting VEGFR2 thiab VEGFR3 (vascular endothelial kev loj hlob receptor).Lub npe lag luam ntawm Lenvatinib yog Lenvima.Nyob rau lub Tsib Hlis 20, 2015, European Medicines Agency (EMA) tau pom zoo Lenvatinib rau kev kho mob ntawm invasive, hauv zos advanced lossis metastatic sib txawv (papillary, follicular, Hurthle type) thyroid cancer (DTC).Hauv kev sim, lub sij hawm ciaj sia nruab nrab rau cov neeg mob ntawm radioactive iodine-refractory DTC kho nrog Lenvatinib yog 18 lub hlis thaum tus nqi rau cov neeg mob uas siv cov placebo tsuas yog 3 lub hlis.

Sau koj cov lus ntawm no thiab xa tuaj rau peb